Port Erin Biopharma Investments Limited ("The Company")
Net Asset Value calculation to 31st March 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2013 was 11.22 pence per share, including un-invested cash of £287,310. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a considerable increase of 18.1% from the previous valuation of 9.50 pence per share, which included un-invested cash of £101,241. The revenue reserve has increased substantially to just over £1.0 million and represents a return of over 37.2% on investments after listing and operating costs."
|
Unaudited to 31 March 2013 £ |
||
|
Fixed Assets |
||
|
Investments |
3,434,606 |
|
|
Current Assets |
||
|
Debtors: amounts owing |
5,690 |
|
|
Un-invested cash |
287,310 |
|
|
Current Liabilities |
||
|
Creditors: amounts due |
(24,000) |
|
|
3,703,606 |
||
|
Capital and Reserves |
||
|
Share Capital |
33 |
|
|
Share Premium |
2,699,011 |
|
|
Capital reserve - realised |
0 |
|
|
Capital reserve - unrealised |
0 |
|
|
Revenue reserve |
1,004,562 |
|
|
3,703,606 |
||
|
Shares in Issue |
33,000,000 |
|
|
Net Asset Value per share |
11.22 pence |
--- ENDS ---
Portfolio Details
|
Investments Schedule at 31st March 2013 |
Valuation £ |
Portfolio % |
|
Synergy Pharmaceuticals Inc. |
318,602 |
9.3% |
|
Gilead Sciences Inc. |
276,677 |
8.1% |
|
Summit Corporation plc |
254,061 |
7.4% |
|
Celgene Corporation |
220,975 |
6.4% |
|
Arrowhead Research |
146,728 |
4.3% |
|
Pfizer Inc. |
140,322 |
4.1% |
|
Biogen Idec Inc. |
139,516 |
4.1% |
|
TrovaGene Inc. |
122,493 |
3.6% |
|
Nektar Therapeutics |
121,507 |
3.5% |
|
1,740,882 |
50.7% |
|
|
Aggregate value of remaining holdings below 3% of total portfolio |
1,693,724 |
49.3% |
|
TOTAL INVESTMENTS |
3,434,606 |
100.0% |
For further information, please contact:
|
Port Erin Biopharma Investments Ltd |
Libertas Capital Corporate Finance Limited |
Peterhouse Capital Limited |
|
The Company |
Nomad |
Broker |
|
Denham Eke +44 162 463 9396 |
Sandy Jamieson +44 207 569 9650 |
Jon Levinson +44 207 562 3350 |
This information is provided by RNS